Metformin Hydrochloride Genus Pharmaceuticals

Metformin, the active ingredient in Metformin Hydrochloride Genus Pharmaceuticals, is a biguanide presented as an oral tablet for oral use. It treats type 2 diabetes mellitus by improving blood glucose control in adult patients.

GNH USA supplies Metformin Hydrochloride Genus Pharmaceuticals as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin is used primarily in the management of disorders related to impaired glucose regulation.

- Type 2 diabetes mellitus: improves glycemic control and reduces HbA1c levels. - Prediabetes: helps lower fasting glucose and delay progression to diabetes.

Metformin may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, often transient. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration of taste perception. - Loss of appetite: reduced desire to eat. - Weight loss: modest reduction in body weight.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic disturbance. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic failure: rare liver dysfunction. - Vitamin B12 deficiency: may develop with long‑term use. - Hypoglycaemia: when combined with other glucose‑lowering agents.

Metformin requires careful patient assessment and monitoring before and during therapy.

- Renal function assessment: avoid or adjust dose in patients with impaired renal clearance. - Hepatic function monitoring: use cautiously in liver disease. - Blood glucose monitoring: regularly check to avoid hypoglycaemia when combined with other agents. - Contra‑indication in severe renal impairment: do not initiate in eGFR <30 mL/min/1.73 m². - Use with caution in elderly: increased risk of lactic acidosis. - Store at ambient temperature: keep in the original pack, protect from moisture.

Metformin can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure and increase lactic acidosis risk. - Cimetidine: can raise metformin plasma concentrations. - Alcohol: potentiates risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - Diuretics: can affect renal function and metformin clearance. - ACE inhibitors: monitor renal function and electrolytes. - Calcium channel blockers: may modestly increase metformin levels. - Warfarin: occasional reports of altered INR, require monitoring.